QLC1101 + panitumumab

**QLC1101 + panitumumab** is an investigational combination regimen being evaluated mainly for the treatment of advanced solid tumors, including metastatic colorectal cancer, harboring specific KRAS mutations (especially G12D and G12C)[3][5][9]. QLC1101 is a novel compound under clinical development (details of its molecular nature, mechanism, and developer are not publicly available except that it is sponsored by Qilu Pharmaceutical), studied in combination with panitumumab for patients with advanced KRAS-mutant solid tumors[5]. Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR signaling and cell proliferation in cancers where EGFR or RAS are wild-type[2][8]. The combination aims to overcome resistance and improve outcomes by inhibiting both KRAS (with QLC1101) and EGFR (with panitumumab)[3][9].